Posted by Michael Wonder on 02 Sep 2020
NICE green light for immunotherapy Bavencio
2 September 2020 - NICE has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
Current NHS treatment for untreated advanced renal cell carcinoma (RCC) includes sunitinib, pazopanib, tivozanib or cabozantinib.
NICE concluded that clinical trial evidence shows that, for people with untreated advanced RCC, Bavencio plus axitinib increases how long people live without their disease getting worse compared with sunitinib, while early data also suggest the therapy increases survival.
